Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP5094 in Rheumatoid Arthritis on Methotrexate
NCT03257852Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2017
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing ASP5094 Group with Placebo Group (2 arms). Primary endpoint: ACR50 response rate at 12 weeks. Started Sep 2017; status: completed.
02
Drugs
ASP5094
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03257852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03257852.